New program delivers whole health behavior change program to
improve member health and deliver valuable insights to Dario's
partners
NEW
YORK, Aug. 2, 2023 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced a new program today to
deliver tailored behavior change support for individuals using
GLP-1s and other anti-obesity drugs. The new program will help
members realize the transformational power of these new medications
while improving overall health and potentially help Dario's
partners gain better insights on the impact across their
populations.
Consumers are driving a surge in demand for GLP-1s and employers
and payers are working to solve for access with a limited
understanding of broader clinical and financial implications. Early
research highlights one key challenge: long-term adoption needed to
realize the full benefits of the medications for both patients and
payers, as two out of three people stop taking the drug in the
first year.
GLP-1s are U.S. Food and Drug Administration-approved for use in
adults with certain related chronic conditions when used in
conjunction with a reduced calorie diet and increased physical
activity. Dario's solution is designed to help people successfully
realize their weight loss goals alongside these medications and
beyond their prescription by focusing on a whole health approach.
Dario's proven combination of innovative technologies and human
support is proven to impact multiple chronic conditions by focusing
on changing the underlying health behaviors.
Billions of data insights from Dario's decade of
direct-to-consumer experience are used to drive highly personalized
journeys focused on driving healthier lifestyle behaviors, and the
new GLP-1 program builds on this approach to deliver long-term
behavior change. Members using a GLP-1 or other anti-obesity
medication who enroll in Dario's cardiometabolic solution will
receive a highly personalized experience optimizing digital
coaching and professional human support to improve overall
health.
Members will also have access to Dario's new Medication Cabinet,
a digital tool developed through collaboration with the Company's
strategic partner, Sanofi US, that allows members to track their
medication adherence. The new feature will help members manage
their overall care and treatment plan in one place through a richer
experience. Data insights available as part of Dario's solution
will help partners better understand member adherence and the
impact on overall member health.
"The standard of care for obesity is evolving, and we believe
Dario's proven ability to sustainably change behaviors will best
help our members and partners realize the full potential of these
anti-obesity medications: long-term weight loss and better overall
health. Our wealth of data insights today guides member engagement
alongside medical weight loss interventions, and this new program
adds a new dimension to the level of insights and guidance we can
provide our partners on this emerging priority," said Rick Anderson, President of Dario.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Our platform and suite of solutions
deliver personalized and dynamic interventions driven by data
analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Our user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
that the new program will help members realize the transformational
power of medications while improving overall health and help
Dario's partners gain better insights on the impact across their
populations, the benefits to be realized by members using the Dario
solution, and data insights available as part of Dario's solution
will help partners better understand member adherence and the
impact on overall member health. Without limiting the generality of
the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
Media Contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
View original
content:https://www.prnewswire.com/news-releases/dario-introduces-glp-1-behavior-change-program-to-help-achieve-weight-loss-goals-and-better-overall-health-outcomes-301891461.html
SOURCE DarioHealth Corp.